Post-effective amendment to a registration statement that is not immediately effective upon filing

CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
shares in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2022
Jun. 30, 2022
Dec. 02, 2021
Dec. 31, 2022
Dec. 31, 2021
CONSOLIDATED STATEMENTS OF CASH FLOWS              
Financial Designation, Predecessor and Successor [Fixed List]   Successor     Predecessor Successor  
Net loss $ (57,938)       $ (146,400) $ (1,561,557)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization 7,149       1,575 87,289  
Equity-based compensation 4,635       3,701 19,404  
Goodwill impairment 0   $ 463,500 $ 851,500   1,314,952  
Amortization of original issue discount and debt issuance costs         1,798    
Accretion of contingent consideration           400  
Gains on changes in fair value of warrants (2,272)       7,665 (9,865)  
Premium deficiency reserve 26,277       11,559 (11,461)  
Changes in operating assets and liabilities:              
Health plan receivable 3,236       (2,770) (21,841)  
Clinic fees, insurance, and other receivables 1,467       (1,485) (5,338)  
Prepaid expenses and other current assets (4,704)       4,254 4,266  
Other long-term assets           100  
Accounts payable, accrued expenses, and other current liabilities 7,732       34,224 6,082  
Accrued payroll 3,159       (1,134) 1,920  
Health plan settlements payable (2,592)       11,265 (8,941)  
Claims payable (971)       19,097 49,249  
Accrued interest (498)       5,216 5,290  
Operating lease liability (22)       306 4,032  
Net cash used in operating activities (15,342)       (51,129) (126,019)  
CASH FLOWS FROM INVESTING ACTIVITIES:              
Purchases of property and equipment (120)       (3,290) (2,233)  
Acquisitions, net of cash acquired (47,879)       (4,989) (5,500)  
Notes receivable 143       70    
Net cash used in investing activities (47,856)       (8,209) (7,733)  
CASH FLOWS FROM FINANCING ACTIVITIES:              
Proceeds from PIPE, net of issuance costs 195,308            
Proceeds from long-term debt, net of original issue discount         25,000 15,000  
Proceeds from short-term debt 3,377       351    
Payment of long-term debt (8)       (186) (46)  
Payment of debt issuance costs         (375)    
Payment of short-term debt           (3,579)  
Net cash provided by financing activities 198,677       24,790 11,375  
Net change in cash and restricted cash 135,479       (34,548) (122,377)  
Cash and restricted cash at beginning of period 5,355       39,903 140,834 $ 39,903
Cash and restricted cash at end of period 140,834 $ 140,834 18,457   5,355 18,457 140,834
Supplemental disclosure of cash flow information:              
Cash paid for interest 1,346       2,796 5,714  
Supplemental disclosures of non-cash investing and financing information:              
Operating lease liabilities arising from obtaining new right-of-use assets 314       4,073 6,839  
Warrants issued in connection with new debt           $ 643  
Increase in accrued expenses related to debt issuance costs and original issue discount           525  
Reconciliation of cash and restricted cash:              
Cash 140,478 140,478 17,537   5,301 $ 17,537 140,478
Restricted cash 356 356 920   54 920 356
Total Cash Balances $ 140,834 $ 140,834 $ 18,457   $ 5,355 $ 18,457 $ 140,834